| Item No | Recommendation | STROBE Statement—Checklist of items that should be included in reports of cohort studies |
|--------|----------------|------------------------------------------------------------------------------------------|
| **Title and abstract** | 1 | *(a)* Indicate the study’s design with a commonly used term in the title or the abstract | Title: Evaluation of a social protection policy on tuberculosis treatment outcomes: A prospective cohort study. |
| | | *(b)* Provide in the abstract an informative and balanced summary of what was done and what was found | The abstract provides this required information. |
| **Introduction** | 2 | Explain the scientific background and rationale for the investigation being reported | The Introduction explains the scientific background and rationale for the investigation |
| **Objectives** | 3 | State specific objectives, including any prespecified hypotheses | Objectives are stated in the last two paragraph of the Introduction. |
| **Methods** | 4 | Present key elements of study design early in the paper | The study design is stated in the Title, the Abstract and the first paragraph of Methods. |
| **Setting** | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Setting and location is specified in paragraph 1 of the Methods section. The dates of data collection are described in paragraph 1 of the Results section. Periods of recruitment, exposure and follow-up are explained in the Procedure section in paragraph 4 of the Methods. |
| **Participants** | 6 | *(a)* Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | The section Study design and participants gives this information in paragraph 1 of Methods. |
| | | *(b)* For matched studies, give matching criteria and number of exposed and unexposed | Number of exposed and unexposed and variable balance achieved by the Propensity score matching are included in paragraph 10 and 11 of Results. |
| Variables         | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | The section *Variable and outcomes* gives these definitions in paragraph 6, 7 and 8 of the Methods section. |
|-------------------|---|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. | Explained in paragraph 5 of Methods under the section *Procedures*. |
| Bias              | 9 | Describe any efforts to address potential sources of bias. | In the section *Statistical Analysis* we explained how we addressed potential bias (paragraph 11 of Methods). |
| Study size        | 10 | Explain how the study size was arrived at. | In paragraph 9 of Methods, under the *Statistical Analysis* we explained how the study size was arrived. |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why. | The detailed analyses are explained in the section *Statistical Analysis*. |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding. | The detailed analyses are explained in the section *Statistical Analysis*. Please also see S1 Propensity Score & IPW adjustment. |
|                   |   | (b) Describe any methods used to examine subgroups and interactions. | Please also see S1 Propensity Score & IPW adjustment. |
|                   |   | (c) Explain how missing data were addressed. | We had a few patients with missing information on the exposure (2.18%) and outcomes (1.6%). They were not included in the analysis. See Fig 1: Flow chart. |
|                   |   | (d) If applicable, explain how loss to follow-up was addressed. | Patients with missing outcome information were not included in the analysis. |
|                   |   | (e) Describe any sensitivity analyses. | Not applicable. |
| Results           | | | |
| Participants      | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined. | Please see Fig 1 (flow chart) and the explanations in the Results section (paragraph 1). |
| **Table** | **Instruction** | **Details** |
|-----------|----------------|------------|
| **Descriptive data** | **14** | **(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders** | Please see Table 1. |
| | | **(b) Indicate number of participants with missing data for each variable of interest** | Please See Fig 1. |
| | | **(c) Summarise follow-up time (e.g., average and total amount)** | Follow-up for our study was 6 months. See paragraph 5 in Methods. |
| **Outcome data** | **15** | **Report numbers of outcome events or summary measures over time** | Not applicable |
| **Main results** | **16** | **(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included** | Explained in tables and Results section. |
| | | **(b) Report category boundaries when continuous variables were categorized** | Not applicable |
| | | **(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period** | Estimated adjusted treatment effects are reported from paragraph 8 in Results section. |
| **Other analyses** | **17** | **Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses** | Please see Statistical analysis and supplementary material (S1 Propensity Score & IPW adjustment). |
| **Discussion** | | | |
| **Key results** | 18 | Summarise key results with reference to study objectives | First paragraph of the Discussion. |
|-----------------|----|--------------------------------------------------------|-----------------------------------|
| **Limitations** | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | In the Discussion section (paragraph 9) |
| **Interpretation** | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | All this items are described in the Discussion section. |
| **Generalisability** | 21 | Discuss the generalisability (external validity) of the study results | Last paragraph of Discussion section. |
| **Other information** | | | |
| **Funding** | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Please see Role of the funding source. |